GLP-1RA治疗2型糖尿病伴非酒精性脂肪性肝病的研究进展  

Research progress of GLP-1RA in the treatment of type 2 diabetes mellitus with non-alcoholic fatty liver disease

作　　者：朱桂华 程方平 王晓梅[2] ZHU Gui-hua;CHENG Fang-ping;WANG Xiao-mei(College of Clinical Medicine,Jining Medical University,Jining 272000,China)

机构地区：[1]济宁医学院临床医学院,272000 [2]枣庄市立医院内分泌代谢科,277000

出　　处：《中国实用医药》2025年第5期163-166,共4页China Practical Medicine

摘　　要：非酒精性脂肪性肝病(NAFLD)是一种与胰岛素抵抗(IR)和遗传易感密切相关的代谢应激性肝损伤,且因共同的影响因素,在2型糖尿病(T2DM)患者中的发病率可达普通人的2倍。目前针对NAFLD的治疗较为局限,主要是通过饮食及运动等生活方式的改变间接进行控制,但因其发病率逐年升高,随着疾病进展可能导致肝硬化、肝癌等不良后果,需要引起重视。新型降糖药物胰高血糖素样肽1受体激动剂(GLP-1RA)具有多重降糖机制,能够减重、改善胰岛素抵抗,且对肝脏脂肪的控制起到有益作用,本文总结了多种GLP-1RA在降糖的同时对NAFLD的影响,以期为NAFLD的治疗提供新思路。Non-alcoholic fatty liver disease(NAFLD)is a metabolic stress liver injury closely related to insulin resistance(IR)and genetic susceptibility.Due to common influencing factors,the incidence rate of non-alcoholic fatty liver disease in type 2 diabetes mellitus(T2DM)patients is twice as high as that in ordinary people.At present,the treatment of NAFLD is relatively limited,and it is mainly controlled indirectly through lifestyle changes such as diet and exercise.However,due to the increasing incidence rate year by year,with the progress of the disease,it may lead to adverse consequences such as cirrhosis and liver cancer,which needs attention.The novel hypoglycemic drug glucagon-like peptide-1 receptor agonist(GLP-1RA)has multiple hypoglycemic mechanisms,can reduce weight,improve insulin resistance,and has beneficial effects on liver fat control.This article summarizes the effects of various GLP-1 receptor agonists on both hypoglycemic and NAFLD,in order to provide new ideas for the treatment of NAFLD.

关 键 词：胰高血糖素样肽1受体激动剂 2型糖尿病 非酒精性脂肪性肝病 

分 类 号：R57[医药卫生—消化系统]